AI Engines For more Details: Perplexity Kagi Labs You
Antineoplastic Activity: Temozolomide is an alkylating agent that works by damaging the DNA of cancer cells, leading to their death. It is effective in slowing down or stopping the growth of cancer cells, particularly in brain tumors.
Brain Tumors: Temozolomide is commonly used in the treatment of glioblastoma multiforme (GBM), which is the most aggressive type of primary brain tumor. It is also used for the treatment of anaplastic astrocytoma, another type of brain tumor.
Oral Administration: Temozolomide is available in oral capsule form, making it convenient for patients to take at home. The dosage and schedule of administration may vary depending on the specific treatment regimen prescribed by a healthcare provider.
Chemotherapy Side Effects: Like other chemotherapy drugs, temozolomide can cause a range of side effects, including nausea, vomiting, diarrhea, loss of appetite, fatigue, hair loss (alopecia), and increased susceptibility to infections. These side effects can vary in severity and may require supportive care or dose adjustments.
Myelosuppression: Temozolomide can suppress the bone marrow's ability to produce blood cells, leading to a decrease in white blood cells (leukopenia), red blood cells (anemia), and platelets (thrombocytopenia). This can result in an increased risk of infection, fatigue, and bleeding tendencies.
Hematologic Toxicity: Hematologic toxicity, including neutropenia (low neutrophil count) and thrombocytopenia (low platelet count), is a common side effect of temozolomide therapy. Close monitoring of blood counts is essential during treatment, and dose adjustments may be necessary to manage hematologic toxicity.
Hepatic and Renal Effects: Temozolomide may cause liver and kidney dysfunction, as evidenced by elevated liver enzymes (AST, ALT) and impaired renal function tests (creatinine, BUN). Patients with pre-existing liver or kidney disease may require dose adjustments or close monitoring during treatment.
Neurological Effects: Temozolomide can cause neurological side effects such as headache, dizziness, and fatigue. In rare cases, it may lead to seizures or exacerbate existing neurological symptoms in patients with brain tumors.
Teratogenicity: Temozolomide can cause fetal harm if administered during pregnancy and is contraindicated in pregnant women. Female patients of childbearing potential should use effective contraception during treatment and for a period after discontinuation of therapy.
Long-term Effects: Temozolomide treatment may have long-term effects on cognitive function and quality of life in survivors of brain tumors. Close monitoring and supportive care are essential to address any long-term complications or sequelae associated with treatment.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.8 | 0.6 | 5.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 2.4 | 2.2 | 0.09 |
| Allergies | 5.2 | 2.9 | 0.79 |
| Allergy to milk products | 1.9 | 1.2 | 0.58 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 4.2 | 5.8 | -0.38 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.1 | 0.8 | 2.88 |
| Ankylosing spondylitis | 3.5 | 0.9 | 2.89 |
| Anorexia Nervosa | 1.2 | 2.6 | -1.17 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 4.5 | 3 | 0.5 |
| Atherosclerosis | 1.2 | 1.6 | -0.33 |
| Atrial fibrillation | 3 | 1.6 | 0.88 |
| Autism | 7.9 | 7 | 0.13 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.8 | 0.8 | |
| Bipolar Disorder | 1.7 | 1.7 | 0 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0 | 0 | |
| Cancer (General) | 0.6 | 2.5 | -3.17 |
| Carcinoma | 3.3 | 2.2 | 0.5 |
| Celiac Disease | 1.2 | 3.3 | -1.75 |
| Cerebral Palsy | 1.6 | 1.3 | 0.23 |
| Chronic Fatigue Syndrome | 4.4 | 4.8 | -0.09 |
| Chronic Kidney Disease | 3.8 | 2.2 | 0.73 |
| Chronic Lyme | 0.5 | 0.8 | -0.6 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.1 | 1.7 | -0.55 |
| Chronic Urticaria (Hives) | 1.4 | 0.6 | 1.33 |
| Coagulation / Micro clot triggering bacteria | 0.9 | 1.3 | -0.44 |
| Cognitive Function | 2.6 | 1.6 | 0.63 |
| Colorectal Cancer | 4.3 | 1.9 | 1.26 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.8 | 2 | -0.11 |
| COVID-19 | 8.4 | 9.8 | -0.17 |
| Crohn's Disease | 4.9 | 4.5 | 0.09 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.6 | 1.9 | -2.17 |
| d-lactic acidosis (one form of brain fog) | 0 | 0 | |
| deep vein thrombosis | 1.1 | 1.4 | -0.27 |
| Denture Wearers Oral Shifts | 1 | 1 | |
| Depression | 8.8 | 8.4 | 0.05 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.4 | 1.4 | 0 |
| Endometriosis | 2.5 | 2 | 0.25 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 2.4 | 1.4 | 0.71 |
| erectile dysfunction | 1.1 | 0.3 | 2.67 |
| Fibromyalgia | 2.6 | 1.5 | 0.73 |
| Functional constipation / chronic idiopathic constipation | 4.1 | 3.2 | 0.28 |
| gallstone disease (gsd) | 2.1 | 1.1 | 0.91 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 1.2 | -3 |
| Generalized anxiety disorder | 2.1 | 2.2 | -0.05 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.3 | 0.7 | 2.29 |
| Graves' disease | 1.5 | 3.3 | -1.2 |
| Gulf War Syndrome | 0.9 | 1.1 | -0.22 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3 | 1.5 | 1 |
| Heart Failure | 2.9 | 1.7 | 0.71 |
| hemorrhagic stroke | 0.6 | 0.6 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 1.1 | 0.6 | 0.83 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.4 | 0.25 |
| hyperglycemia | 1.9 | 1.4 | 0.36 |
| Hyperlipidemia (High Blood Fats) | 0.8 | 0.3 | 1.67 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 4.1 | 5 | -0.22 |
| Hypothyroidism | 0.2 | 1 | -4 |
| Hypoxia | 2.5 | 0.3 | 7.33 |
| IgA nephropathy (IgAN) | 1.2 | 3.3 | -1.75 |
| Inflammatory Bowel Disease | 5.9 | 7.4 | -0.25 |
| Insomnia | 1.9 | 3.1 | -0.63 |
| Intelligence | 0.8 | 0.2 | 3 |
| Intracranial aneurysms | 0.7 | 0.6 | 0.17 |
| Irritable Bowel Syndrome | 6.6 | 4.3 | 0.53 |
| ischemic stroke | 2.2 | 1.7 | 0.29 |
| Liver Cirrhosis | 6.2 | 4.4 | 0.41 |
| Long COVID | 6.1 | 7.1 | -0.16 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.2 | 1.5 | -0.25 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 1.2 | 2.3 | -0.92 |
| ME/CFS without IBS | 1.4 | 1.8 | -0.29 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.8 | 1.63 |
| Metabolic Syndrome | 5.8 | 6.3 | -0.09 |
| Mood Disorders | 9.5 | 7 | 0.36 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 5.7 | 4 | 0.43 |
| Multiple system atrophy (MSA) | 1.4 | 0.7 | 1 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 2.9 | -8.67 |
| Neuropathy (all types) | 0.9 | 1.7 | -0.89 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.2 | 5.1 | 0.02 |
| NonCeliac Gluten Sensitivity | 1.7 | 0.6 | 1.83 |
| Obesity | 9.6 | 6.5 | 0.48 |
| obsessive-compulsive disorder | 3.9 | 3.5 | 0.11 |
| Osteoarthritis | 2 | 1.4 | 0.43 |
| Osteoporosis | 2.5 | 1.7 | 0.47 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 7.2 | 5.3 | 0.36 |
| Polycystic ovary syndrome | 3.9 | 2.9 | 0.34 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.7 | |
| primary biliary cholangitis | 1.2 | 0.8 | 0.5 |
| Primary sclerosing cholangitis | 1.8 | 1.5 | 0.2 |
| Psoriasis | 3 | 1.9 | 0.58 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.8 | 3.4 | 1 |
| Rosacea | 1 | 0.7 | 0.43 |
| Schizophrenia | 5.8 | 2.8 | 1.07 |
| scoliosis | 0.3 | 0.7 | -1.33 |
| Sjögren syndrome | 2.4 | 2.2 | 0.09 |
| Sleep Apnea | 1.9 | 1.8 | 0.06 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 0.6 | 1.33 |
| Stress / posttraumatic stress disorder | 2.2 | 2.7 | -0.23 |
| Systemic Lupus Erythematosus | 2.7 | 1.8 | 0.5 |
| Tic Disorder | 0.9 | 1.4 | -0.56 |
| Tourette syndrome | 1.1 | 0.3 | 2.67 |
| Type 1 Diabetes | 3.4 | 3.8 | -0.12 |
| Type 2 Diabetes | 6.6 | 5.1 | 0.29 |
| Ulcerative colitis | 3.8 | 4.9 | -0.29 |
| Unhealthy Ageing | 3.5 | 1.8 | 0.94 |
| Vitiligo | 1.5 | 1.3 | 0.15 |
